



Conference Call Alert

Planegg/Munich, Germany, July 25, 2019

Invitation to MorphoSys Q2 2019 Conference Call on August 7, 2019

MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; Nasdaq: MOR) will publish its first six months' 2019 results on August 6, 2019 at 10:00pm CEST (9:00pm BST; 4:00pm EDT).

The Management team of MorphoSys AG will host a conference call and webcast on August 7, 2019 at 2:00pm CEST (1:00pm BST; 8:00am EDT) to present MorphoSys's Half-Year-Report 2019 and provide further details on the Company's latest developments.

Date of the conference call:	Wednesday, August 7, 2019
Time:	2:00pm CEST (1:00pm BST, 8:00am EDT)
Dial-in numbers (listen only)	
Germany:	+49 69 201 744 220
United Kingdom:	+44 203 009 2470
USA:	+1 877 423 0830
Participant PIN:	43166710#

Participants are kindly requested to dial in up to 10 minutes before the call to ensure a secure line and a prompt start.

The presentation slides and webcast link will be available at the Company's website at <http://www.morphosys.com/conference-calls>

A replay of the conference will also be available at the corporate website following the live event.

About MorphoSys:

MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 29 are currently in clinical development. In 2017, Tremfya[®], marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys's antibody technology to receive regulatory approval. The Company's most advanced proprietary product candidate, tafasitamab (MOR208), has been granted U.S. FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has approximately 330 employees. More information at <https://www.morphosys.com>.

HuCAL[®], HuCAL GOLD[®], HuCAL PLATINUM[®], CysDisplay[®], RapMAT[®], arYla[®], Ylanthia[®], 100 billion high potentials[®], Slonomics[®], Lanthio Pharma[®] and LanthioPep[®] are registered trademarks of the MorphoSys Group. Tremfya[®] is a trademark of Janssen Biotech, Inc.

MorphoSys forward looking statements

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys's results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys's expectations may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that MorphoSys may fail to obtain regulatory approval for tafasitamab (MOR208) and that data from MorphoSys's ongoing clinical research programs may not support registration or further development of its product candidates due to safety, efficacy or other reasons), MorphoSys's reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys's Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

For more information, please contact:

MorphoSys AG

Dr. Sarah Fakhri
Head of Corporate Communications & IR

Dr. Julia Neugebauer
Director Corporate Communications & IR

Dr. Verena Kupas
Manager Corporate Communications & IR

Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com